HAEM5:Gamma heavy chain disease: Difference between revisions

[checked revision][checked revision]
No edit summary
No edit summary
Line 84: Line 84:




<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Clinical Features|The content below was from the old template. Please incorporate above.}}</blockquote>




Line 116: Line 116:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":2" /></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":2" /><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>
</blockquote>
==Sites of Involvement==
==Sites of Involvement==
Line 142: Line 148:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":3" /></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":3" /><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==Immunophenotype==
==Immunophenotype==


Line 161: Line 170:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":3" /></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":3" /><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==Chromosomal Rearrangements (Gene Fusions)==
==Chromosomal Rearrangements (Gene Fusions)==


Line 185: Line 197:


<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}</blockquote>


*No consistent gene fusions<ref>{{Cite journal|last=Witzig|first=Thomas E.|last2=Wahner-Roedler|first2=Dietlind L.|date=2002-06|title=Heavy chain disease|url=https://pubmed.ncbi.nlm.nih.gov/12057070|journal=Current Treatment Options in Oncology|volume=3|issue=3|pages=247–254|doi=10.1007/s11864-002-0014-3|issn=1527-2729|pmid=12057070}}</ref>
*No consistent gene fusions<ref>{{Cite journal|last=Witzig|first=Thomas E.|last2=Wahner-Roedler|first2=Dietlind L.|date=2002-06|title=Heavy chain disease|url=https://pubmed.ncbi.nlm.nih.gov/12057070|journal=Current Treatment Options in Oncology|volume=3|issue=3|pages=247–254|doi=10.1007/s11864-002-0014-3|issn=1527-2729|pmid=12057070}}</ref>


<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>


Line 196: Line 211:
* Individual Region Genomic Gain/Loss/LOH
* Individual Region Genomic Gain/Loss/LOH
* Characteristic Chromosomal Patterns
* Characteristic Chromosomal Patterns
* Gene Mutations (SNV/INDEL)}}
* Gene Mutations (SNV/INDEL)}}</blockquote>




Line 202: Line 217:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":4">{{Cite journal|last=Singer|first=Sara|last2=Efebera|first2=Yvonne|last3=Bumma|first3=Naresh|last4=Khan|first4=Abdullah|last5=Devarakonda|first5=Srinivas|last6=Chaudhry|first6=Maria|last7=Benson|first7=Don|last8=Rosko|first8=Ashley E.|date=2020-08|title=Heavy Lifting: Nomenclature and Novel Therapy for Gamma Heavy Chain Disease and Other Heavy Chain Disorders|url=https://pubmed.ncbi.nlm.nih.gov/32245744|journal=Clinical Lymphoma, Myeloma & Leukemia|volume=20|issue=8|pages=493–498|doi=10.1016/j.clml.2020.02.020|issn=2152-2669|pmid=32245744}}</ref></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":4">{{Cite journal|last=Singer|first=Sara|last2=Efebera|first2=Yvonne|last3=Bumma|first3=Naresh|last4=Khan|first4=Abdullah|last5=Devarakonda|first5=Srinivas|last6=Chaudhry|first6=Maria|last7=Benson|first7=Don|last8=Rosko|first8=Ashley E.|date=2020-08|title=Heavy Lifting: Nomenclature and Novel Therapy for Gamma Heavy Chain Disease and Other Heavy Chain Disorders|url=https://pubmed.ncbi.nlm.nih.gov/32245744|journal=Clinical Lymphoma, Myeloma & Leukemia|volume=20|issue=8|pages=493–498|doi=10.1016/j.clml.2020.02.020|issn=2152-2669|pmid=32245744}}</ref><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>
</blockquote>
==Individual Region Genomic Gain / Loss / LOH==
==Individual Region Genomic Gain / Loss / LOH==
Line 251: Line 272:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Genomic Gain/Loss/LOH|The content below was from the old template. Please incorporate above.}}</blockquote>




Line 258: Line 279:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":1" /><ref name=":5" /></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":1" /><ref name=":5" /><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>
</blockquote>
==Characteristic Chromosomal Patterns==
==Characteristic Chromosomal Patterns==
Line 283: Line 310:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}</blockquote>


*No consistent pattern reported
*No consistent pattern reported


<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>
==Gene Mutations (SNV / INDEL)==
==Gene Mutations (SNV / INDEL)==
Line 345: Line 375:
|}
|}


<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}</blockquote>


* N/A
* N/A


<blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
</blockquote>
==Genetic Diagnostic Testing Methods==
==Genetic Diagnostic Testing Methods==
Line 362: Line 395:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal|last=Mrosewski|first=Ingo|last2=Urbank|first2=Matthias|date=2020-01-01|title=Gamma Heavy Chain Disease - Diagnostic Challenges in an Unusual Case and a Brief Synopsis of the Current Literature|url=https://pubmed.ncbi.nlm.nih.gov/32013371|journal=Clinical Laboratory|volume=66|issue=1|doi=10.7754/Clin.Lab.2019.190623|issn=1433-6510|pmid=32013371}}</ref><ref>{{Cite journal|last=Thoren|first=Katie L.|last2=Eveillard|first2=Marion|last3=Chan|first3=Patrick|last4=Doddi|first4=Sital|last5=Cho|first5=Sun|last6=Murata|first6=Kazunori|date=2020-03|title=Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry|url=https://pubmed.ncbi.nlm.nih.gov/31884198|journal=Clinical Biochemistry|volume=77|pages=57–61|doi=10.1016/j.clinbiochem.2019.12.010|issn=1873-2933|pmc=7046309|pmid=31884198}}</ref><ref>{{Cite journal|last=Ho|first=Y. H.|last2=Wang|first2=J. L.|last3=DeLelys|first3=M. E.|last4=Murali|first4=M. R.|last5=Pitman|first5=M. B.|last6=Sohani|first6=A. R.|date=2014-08|title=Gamma heavy chain disease: cytological diagnosis of a rare  lymphoid malignancy facilitated by correlation with key  laboratory findings|url=https://pubmed.ncbi.nlm.nih.gov/25180407|journal=Cytopathology: Official Journal of the British Society for Clinical Cytology|volume=25|issue=4|pages=270–273|doi=10.1111/cyt.12126|issn=1365-2303|pmid=25180407}}</ref></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal|last=Mrosewski|first=Ingo|last2=Urbank|first2=Matthias|date=2020-01-01|title=Gamma Heavy Chain Disease - Diagnostic Challenges in an Unusual Case and a Brief Synopsis of the Current Literature|url=https://pubmed.ncbi.nlm.nih.gov/32013371|journal=Clinical Laboratory|volume=66|issue=1|doi=10.7754/Clin.Lab.2019.190623|issn=1433-6510|pmid=32013371}}</ref><ref>{{Cite journal|last=Thoren|first=Katie L.|last2=Eveillard|first2=Marion|last3=Chan|first3=Patrick|last4=Doddi|first4=Sital|last5=Cho|first5=Sun|last6=Murata|first6=Kazunori|date=2020-03|title=Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry|url=https://pubmed.ncbi.nlm.nih.gov/31884198|journal=Clinical Biochemistry|volume=77|pages=57–61|doi=10.1016/j.clinbiochem.2019.12.010|issn=1873-2933|pmc=7046309|pmid=31884198}}</ref><ref>{{Cite journal|last=Ho|first=Y. H.|last2=Wang|first2=J. L.|last3=DeLelys|first3=M. E.|last4=Murali|first4=M. R.|last5=Pitman|first5=M. B.|last6=Sohani|first6=A. R.|date=2014-08|title=Gamma heavy chain disease: cytological diagnosis of a rare  lymphoid malignancy facilitated by correlation with key  laboratory findings|url=https://pubmed.ncbi.nlm.nih.gov/25180407|journal=Cytopathology: Official Journal of the British Society for Clinical Cytology|volume=25|issue=4|pages=270–273|doi=10.1111/cyt.12126|issn=1365-2303|pmid=25180407}}</ref><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==Familial Forms==
==Familial Forms==


Line 384: Line 420:




<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":4" /></blockquote>
<blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref name=":4" /><blockquote class="blockedit">
<center><span style="color:Maroon">'''End of V4 Section'''</span>
----
</blockquote>
==Links==
==Links==